Contact
/
Home
/
About
Team
Portfolio
Exit History
News
About
Team
Portfolio
Exit History
News
Advent Life Sciences
Advent Life Sciences
Page 6 of 24
<< Start
< Prev
1
2
3
4
5
6
7
8
9
10
Next >
End >>
05.01.2021
Aura Biosciences Appoints David Johnson to Its Board of Directors
Press Release
22.10.2020
F2G Receives Second US FDA Breakthrough Therapy Designation for Olorofim
Press Release
13.10.2020
Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs
Press Release
02.09.2020
Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis
Press Release
12.08.2020
PIC Therapeutics Appoints Dr. Katherine Bowdish as Chief Executive Officer
Press Release
12.08.2020
F2G Closes US$60.8 Million Financing to fund late stage development of novel mechanism antifungal agent
Press Release
11.08.2020
Advent Life Sciences announces sale of its portfolio Company KaNDy Therapeutics to Bayer AG for USD 425M upfront plus USD 450M in potential development milestones followed by further potential commercial milestones.
Press Release
06.08.2020
Acutus Medical Announces Pricing of Initial Public Offering
Press Release
17.07.2020
Zikani Therapeutics Appoints Chief Scientific and Medical Officer
Press Release
24.06.2020
Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158
Press Release
©2022 Advent Life Sciences